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 Homology models of Sitruin4 were built and evaluated.  
 A Sirtuin4 model complexed with NAD+ and glutamate dehydrogenase was built.  
 Acetylated Lys171 of glutamate dehydrogenase and NAD+ were close to each other.  
 These suggest the mechanism of ADP-ribosylation of glutamate dehydrogenase.  
 
Abstract 
Sirtuin4 (Sirt4) is one of the mammalian homologues of Silent information regulator 2 
(Sir2), which promotes the longevity of yeast, C. elegans, fruit flies and mice. Sirt4 is 
localized in the mitochondria, where it contributes to preventing the development of 
cancers and ischemic heart disease through regulating energy metabolism. The 
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downregulates the TCA cycle. However, this reaction mechanism is obscure, because the 
structure of Sirt4 is unknown. We here constructed structural models of Sirt4 by 
homology modeling and threading, and docked nicotinamide adenine dinucleotide+ 
(NAD+) to Sirt4. In addition, a partial GDH structure was docked to the Sirt4-NAD+ 
complex model. In the ternary complex model of Sirt4-NAD+-GDH, the acetylated lysine 
171 of GDH is located close to NAD+. This suggests a possible mechanism underlying the 
ADP-ribosylation at cysteine 172, which may occur through a transient intermediate 
with ADP-ribosylation at the acetylated lysine 171. These results may be useful in 
designing drugs for the treatment of cancers and ischemic heart disease.   
 
Abbreviations 
GDH Glutamate dehydrogenase  
GDH 158–187 Residues 158–187 of human GDH 
NAD Nicotinamide adenine dinucleotide 
RMSD Root-mean-square deviation 
RMSF Root-mean-square fluctuation 
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1. Introduction  
   Silent information regulator 2 (Sir2) genes have been shown to expand the lifespans of 
yeast, C. elegans, fruit flies, and mice [1-4]. Sirtuin4 (Sirt4) is one of seven mammalian gene 
products of Sir2 homologues. Many of the Sir2 family enzymes display nicotinamide adenine 
dinucleotide+ (NAD+)-dependent deacetylase activity. Sirt4 was previously reported to lack 
deacetylase activity [5]; however, recent studies have indicated the possibility of deacetylase 
and delipoylase activities [6-9]. In addition, Sirt4 catalyzes the ADP-ribosylation of glutamate 
dehydrogenase (GDH) with NAD+ as a substrate [5]. The activity of GDH is inhibited by 
ADP-ribosylation of the C172 residue at the active site of GDH [5, 10]. Sirt4 is localized at 
the mitochondria, where it regulates the energy metabolic pathways, such as the TCA cycle 
and the oxidation of fatty acids by downregulating the activities of GDH and malonyl CoA 
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tumor development by downregulating GDH and, in turn, the TCA cycle [11]. In contrast, the 
TCA cycle is activated in cancer cells, because the expression of Sirt4 is suppressed by the 
mammalian target of rapamycin complex 1, mTORC1. Furthermore, Sirt4 is likely to play a 
crucial role in preventing cardiomyocyte loss during ischemic heart injury presumably 
through the regulatory mechanisms of energy metabolism [12].  
   The mechanism for the ADP-ribosylation of GDH by Sirt4 remains obscure because the 
structure of Sirt4 has been unknown. Because the mechanism by which Sirt4 regulates GDH 
is unclear, there has been a delay in drug design studies that target Sirt4 to treat cancer and 
ischemic heart disease. Recent progress in the field of prediction of protein structure and 
ligand binding modes has been remarkable [13, 14][15]. In the present study, we aimed to 
construct a structural model of a complex of human Sirt4 and GDH in order to elucidate the 
molecular mechanism underlying the ADP-ribosylation of GDH by Sirt4.  
 
2. Materials and Methods  
2.1. The modeling of the Sirt4-NAD+ complex 
   We aligned Sir2 homologues with clustal W to determine the modeling region in the 
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Sirt4 was carried out with the sequence covering residue 40–314 using SWISS-MODEL [16] 
and Robetta [17]. I-TASSER, which ranked top in the recent Critical Assessment of 
Techniques for Protein Structure Prediction (CASP) contests, was used for threading [18]. The 
structural refinement of the models was performed by energy minimization using Swiss PDB 
Viewer with a partial implementation of the GROMOS96 force field [16]. The Sirt4 models 
were evaluated by PROCHECK [19], Verify3D [20], ERRAT [21] and energy calculation. 
The energy calculation was performed using Swiss PDB Viewer and the score function 
provided by the Rosetta suite [22]. The ENCoM server, which is used in the normal-mode 
analysis of coarse-grained models, was used to predict global structural changes [23]. A 
coarse-grained normal-mode analysis is suitable for predicting the large structural changes of 
proteins with relatively low CPU requirements. NAD+ was docked with AutoDock Vina [24]. 
The scoring function of AutoDock Vina is based on “machine learning” rather than the 
physics-based energy potential. The accuracy of the prediction using a training set was ~80% 
based on an RMSD cutoff of 2 Å. The coordinates of NAD+ were extracted from a PDB file 
of a Sir2 homologue complexed with NAD+ (PDB code: 1ICI). The structures of the Sirt4 
models and NAD+ were prepared with the addition of gasteiger charges and polar hydrogens 
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structures were produced with Swiss PDB viewer.  
 
2.2. Docking of the GDH fragment  
   We predicted sites that showed a high propensity for binding on the surface of a Sirt4 
model by STP [26]. Prediction by STP is based on the amino acid triplet types on the protein 
surface. STP predicts the top three binding sites on a protein with 88% accuracy.  
   The crystal structure of human GDH (PDB code: 1L1F) was downloaded from Protein 
Data Bank [27]. The coordinates of residues 158–187 of human GDH (GDH 158–187) were 
extracted from the PDB file for docking. Rigid body docking was carried out with the 
ZDOCK server [28] using a Sirt4 model and the coordinates of GDH 158–187. ZDOCK can 
predict the binding modes of protein-protein interaction with no experimental constraints. The 
scoring function of the ZDOCK server scores the shape complementarity, electrostatic charge, 
and interface atomic contact energy potential [29]. To allow for complete automation, no 
constraint was set for the docking simulation of GDH 158–187. The top 5 output models were 
observed in the docking trial. To confirm the ZDOCK result, rigid body docking was carried 
out using ClusPro without constraints. In the recent Critical Assessment of Prediction of 











Kato et al. 2017 
 8 
among the automated servers [30].  
   Docking with the flexible GDH fragments was performed with FlexPepDock using the 
top 2 model of ZDOCK as a template [31]. FlexPepDock takes advantage of the framework of 
the Rosetta ab initio modeling suite to predict protein-peptide docking modes, and produces 
highly accurate models with an RMSD cutoff of 2 Å in more than 90% of the test sequences. 
The docking of the GDH fragments acetylated at lysine 171 was performed using AutoDock 
Vina.   
 
2.3. The molecular dynamics simulations 
   After docking with AutoDock Vina, the complex model of Sirt4-NAD+-GDH 158–187 
was subjected to molecular dynamics (MD) simulations. The Amber ff14SB force field was 
applied to the complex [32]. The protein complex was placed in a periodic TIP3P box with 
the LEaP module of AMBER 14 [33]. The system was neutralized by replacing several TIP3P 
molecules with Cl- ions. A 10-Å cut-off was applied to the non-bonded interactions according 
to the Lennard–Jones potential. Steepest descent minimization was performed followed by 
conjugate gradient minimization with the Particle Mesh Ewald method with constant-volume 
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procedure was performed from 0 to 300 K under constant volume periodic boundaries. 
Equilibration and production MD were carried out for 10 ns with a constant pressure periodic 
boundary at 1 atm and 300 K without position restraints. The MD simulations for acetylated 
GDH 158–187 were performed under the same conditions.  
 
2.4. Calculation of the binding free energy of NAD+ 
   The binding free energy (ΔGbind) of the interaction between NAD
+ and the Sirt4 model 
was calculated based on the molecular mechanics energies combined with the generalized 
Born and surface area (MM/GBSA) method implemented in the AmberTools14 suite [34] [35]. 
The energy components including the molecular mechanical energy (ΔEMM) and solvation 
energy (ΔGsolv) were defined as below [36]. The entropy term (TΔSMM) was calculated based 
on the quasi-harmonic approximation [37].  
ΔGbind = ΔG
MM + ΔGsolv = ΔHbind - TΔS
MM 
ΔGMM = ΔEMM - TΔSMM 
ΔHbind = ΔE
MM + ΔGsolv 
ΔEMM =ΔEvdw + ΔEelec 

















3.1. Building the Sirt4 model 
   We carried out the homology modeling of amino acid residues 40–314 of human Sirt4 
using SWISS-MODEL and Robetta (Fig 1). Homology modeling accurately predicts protein 
structures when there is more than ~30% identity between a target sequence and template 
structures [38]. It becomes difficult to align a target sequence with the sequence of a template 
structure when the identity is less than 30%, as this leads to significant errors in the model 
structure. Table 1 shows the identities and coverage between the Sirt4 sequence and the 
template structures that were used in the homology modeling. All of the templates in Table 1 
had >30% identity but did not have 100% coverage; thus the applicability of homology 
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Fig 1. The alignment of the Sir2 
homologues 
hSirt4, afSir2, hSirt5 and zSirt5 stand 
for human Sirt4, Archaeoglobus 
fulgidus Sir2, human Sirt5 and 
zebrafish Sirt5, respectively. The 
residue numbers of human Sirt4 are 
shown. The locations of -helices 
(cylinders) and -strands (arrows) of 
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   In contrast, threading can be applied to model sequences that show much lower identity to 
templates. Thus, in addition to homology modeling, we carried out threading using I-TASSER, 
which can construct accurate structural models with low sequence identities to templates [39, 
40]. I-TASSER uses multiple scoring profiles for a target sequence and multiple structural 
templates from Protein Data Bank, and then constructs a model by assembling the template 
fragments. 
   SWISS-MODEL, Robetta and I-TASSER each produced multiple models, which 
appeared similar to each other (Fig 2A). The superposition of all of the models showed that 
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Fig 2. The model structures of Sirt4 
(A) The models constructed in the present study are shown for comparison. The models in the top, middle 
and bottom rows were constructed by SWISS-MODEL, Robetta, and I-TASSER, respectively.  
(B) All the models shown in (A) are superposed.  
 
   To select the most appropriate models, we evaluated the models in terms of PROCHECK, 
Verify3D, ERRAT and energy calculation. The models from Robetta showed no disallowed 
residues in the Ramachandran plots produced by PROCHECK, whereas the other models 
showed several disallowed residues (Table 2). The Robetta models showed larger numbers of 
favored residues than the other models. Verify3D and ERRAT also suggested high quality of 
the Robetta models (Tables 3 and 4). In addition, energy calculation by two different methods 
revealed that the Robetta models showed the lowest values (Table 5). A coarse-grained 
normal-mode analysis was performed to confirm the structural stability. The results predicted 
that the overall fold of the Robetta model was maintained while dynamic structural changes 
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Fig 3. The dynamic structural motion of 
Sirt4 model 
This illustration is based on the results from 
the coarse-grained normal-mode analysis with 




3.2. The Docking of NAD+  
   Sirt4 uses NAD+ as a substrate for ADP-ribosylation (Figs. 4A and B). We therefore 
examined the docking of NAD+ to the Robetta models using AutoDock Vina. The docking 
results indicated that NAD+ docked with the interior grooves of the 4th Robetta model with a 
pose that was similar to those observed in the structures of the other Sir2 proteins (Fig 4C). In 
contrast, NAD+ docked with different grooves in the other Robetta models. This suggests that 
only the 4th model possessed a similar groove structure to the other Sir2 proteins; however, 
the docking poses of NAD+ with the 4th model still showed minor variation (Fig 4D). While 
the docked NAD+ poses showed variation in the locations of the nicotinamide and adenine 
residues, one of the poses showed high similarity to that of NAD+ in a crystal structure of 
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the other poses, suggesting that this is the most plausible possibility. Nicotinamid (NCA) is an 
inhibitor against Sirt4 and docked with the interior groove of the 4th model with a similar 
pose to the NCA group of NAD+ (Fig. 4E). This also supported the validity of the structure of 
the 4th model.    
 
Fig 4. A model of the Sirt4-NAD+ complex 
(A) The structural formula of NAD+. Reactive C1’ 
is colored red.  
(B) The chemical equation of the reaction 
catalyzed by Sirt4.  
(C) The surface representation of a complex model 
of Sirt4-NAD+. The surface of the Sirt4 model is 
transparent, whereas NAD+ is shown as a blue 
nontransparent object. This panel was made with 
UCSF Chimera [43]. 
(D) Configurations of NAD+ docked to Sirt4 as 
well as that of NAD+ in complex with human Sirt5 
(cyan, PDB code: 4G1C) are superposed. The 
configuration that docked best with Sirt4, which is 
also shown in (C), is colored orange.  
(E) Docking with NCA. Ribbon models of afSir2 
(PDB code: 1YC2), Sir2 from Thermotoga 
maritima (PDB code: 1YC5) and the 4th Robetta 
model of Sirt4 are colored sky blue, green and 
gray, respectively. NCA docked with the 4th 
model was depicted in CPK coloring, whereas 
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3.3. The docking of the GDH fragment  
   It has been suggested that Sirt4 ADP-ribosylates C172 at the active site of GDH using 
NAD+ [5, 10]. In the proposed mechanism of ADP-ribosylation by Sir2 proteins from 
microorganisms, an acetylated lysine residue of a substrate protein is first ADP-ribosylated to 
form a reaction intermediate, followed by the translocation of the ADP-ribosyl group to the 
final site of ADP-ribosylation [44, 45]. 
   It should be noted that the acetyl lysine and the final ADP-ribosylation site should be 
accessible to each other for the translocation. Similarly to other mitochondrial proteins, 
multiple lysine residues of GDH are acetylated [42, 46, 47]. Among these, K171 is the closest 
acetylation site to C172 (Fig 5A). Thus, K171 of GDH is likely to play an important role in 
the ADP-ribosylation at C172. This is compatible with the finding that the glutamate residue 
next to acetylated Lys15 is ADP-ribosylated in histone H1.1, which is a possible substrate of 
















Fig 5. The sequence and structure of GDH 
(A) The full length of the human GDH sequence. Green and magenta shading indicates the sites of 
acetylation and ADP-ribosylation, respectively. The orange box indicates K171 and C172.  
(B) The region of 158–187 of GDH, GDH 158–187, forming a helix-loop-strand configuration.   
(C) The dynamic structural motion of GDH 158 - 187 was simulated with a coarse-grained normal-mode 
analysis.  
 
   Fig 5B shows relative locations of K171 and C172 in the crystal structure of GDH [49]. 
These residues are located at an edge of the 158–173 helix, followed by the bending 174–179 
loop and the extended 180–187 strand. We call this region GDH 158–187. To predict the 
structural change of GDH 158–187, we performed a coarse-grained normal-mode analysis 
with the ENCoM server [23], and found no change of the global fold of GDH 158–187 (Fig 
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so that we used the GDH 158–187 coordinates for docking to the Sirt4 model.  
   Prior to the docking simulation, we investigated sites on the surface of the Sirt4 model 
that showed a high propensity for binding using STP, and found high propensity sites around 
the center of the model (circled in Fig 6A). Using the ZDOCK server, we then carried out 
automated rigid body docking between the Sirt4 model and the helix-loop-strand structure of 
GDH 158 –187. We found that GDH 158–187 was docked into a hole composed of the 63–91 
loop of Sirt4, and that K171 of GDH was located close to NAD+ (Fig 6B). This result is 
consistent with the STP result. Moreover, a rigid body docking simulation with ClusPro 
































Fig 6. Docking GDH to Sirt4  
(A) The prediction of the propensity of the binding sites mapped on the Sirt4 model. The hot and cold colors 
indicate high and low propensity sites, respectively. A cluster of high propensity sites is circled. This panel 
was made with PyMol (Schrödinger, LLC., New York, NY). 
(B) The results of rigid body docking using ZDOCK. GDH 158–187 was docked to the Sirt4 model. GDH 
158–187 and Sirt4 are depicted as yellow and light gray ribbons, respectively. NAD+ is depicted as a stick 
model. The illustration shows the second-ranked model in the docking simulation. The top-ranked model of 
GDH 158–187 docking was unrealistic, because the N- and C-termini were buried in Sirt4. We note that 
GDH 158–187 is a part of GDH; thus, in reality, the N- and C-termini are connected to the rest of the GDH 
sequence. The illustrated model has exposed N- and C-termini, which is necessary for connection to the rest 
of the GDH sequence.  
(C) The results of rigid body docking using ClusPro. The illustration shows the top-ranked model. The 
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(D) The results of flexible docking. The structure of GDH 158–187 (magenta) was flexibly perturbed and 
docked to the Sirt4 model.  
(E) The results of the docking of the acetylated GDH fragment. GDH 158–187 (yellow) with acetylated 
K171 was docked to Sirt4. The 63–91 loop of Sirt4 is indicated in green.  
(F) A magnified view of (E) 
 
   To obtain a refined docking pose, we carried out flexible docking with FlexPepDock in 
which the structure of GDH 158–187 was flexibly perturbed by the conformational sampling 
protocols that are implemented in the Rosetta suite. A docking solution indicated a pose in 
which the GDH model with an altered structure was docked into the hole composed of the 
63–91 loop, while the overall structure of the GDH fragment was similar to that of the crystal 
structure (Fig 6D).  
   FlexPepDock does not take the modifications of amino acids and cofactors into account. 
We therefore examined the docking of acetylated GDH 158–187 to the complex of 
Sirt4-NAD+ using AutoDock Vina. The results showed that acetylated GDH 158–187 in the 
helix-loop-strand conformation was docked to Sirt4 with NAD+ in a similar pose to that which 
was output by FlexPepDock (Figs 6E and F). We evaluated the docking model and found that 
the results from PROCHECK, Verify3D, ERRAT and the energy calculations indicated no 
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loop fringed the docked GDH 158 - 187 model in the ternary complex model (Fig. 6E). This 
loop was detached from the main fold of Sirt4, forming a hole. Such a hole is also present on 
the surface of afSir2 [50].   
 
3.4. Dynamic properties of the Sirt4-NAD+-GDH model  
   In order to examine the extent of the structural stability of the Sirt4-NAD+-GDH model, 
an MD simulation was performed. The RMSD of the complex model tended to converge after 
4 ns. This suggested that the complex structure of the model was stable and that it had reached 
an equilibrium, supporting the validity of the complex model (Fig. 7A). The RMSD between 
the initial and final trajectories of the main fold of Sirt4 was ~2.8Å, which suggested the 
stability of the global fold of the Sirt4 model. (Fig 7B). The root-mean-square fluctuation 
(RMSF) was calculated to evaluate the dynamic properties of the complex. Residues 77–80, 
190–210 and 221–224 of Sirt4 and the N- and C- termini of acetylated GDH 158–187 were 
flexible (Fig. 7C, D). The flexible regions were mapped on the Sirt4 model structure (Fig. 
7E). Residues 190–210 formed a long loop structure at the top of the model. Residues 77 –80 
belonged to the 63–91 loop.  
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rotated clockwise relative to the Rossmann domain of Sirt4 (Fig. 7B) and many hydrogen 
bonds formed or strengthened between NAD+ and the Rossmann domain (Table 7, Fig. 7F). 
The formation of the hydrogen bonds was accompanied by the conformational change in the 
Rossman domain and NAD+. The 261-267 loop moved toward NAD+ by the shortening of the 
hydrogen bond between S262 and the phosphate group of NAD+ (Fig. 7B, F). As a 
consequence, GDH 158 – 187 was pushed away and the structure of the 92 – 96 helix and the 















Fig 7. Dynamic properties the Sirt4-NAD+- GDH 158–187 model 
(A) The RMSD values of the backbone Cα atoms in the course of the MD simulation of the Sirt4-NAD+- 
GDH 158–187 model.  
(B) Comparison of the structures before (gray) and after (cyan) the MD simulation.  
(C) The RMSF of Sirt4 in complex with NAD+ and GDH 158–187. The RMSD values of individual residues, 
which were calculated from the trajectories of the MD simulations after 5 ns, are plotted.   
(D) The RMSF of GDH 158–187 in the complex. 
(E) The mapping of the flexible regions on the Sirt4 model. The amino acid residue numbers of the colored 
regions are indicated.  
(F) An enlarged view of the ternary complex model after the MD simulation. NAD+ and the residues that 
formed hydrogen bonds with NAD+ are depicted as stick models. Hydrogen bonds between NAD+ and Sirt4 
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   It is natural to question how C172 is ADP-ribosylated. In the ADP-ribosylation 
mechanism proposed for Sir2 proteins from microorganisms, ADP-ribosylation is mediated 
through the formation of a transient intermediate with acetylated lysine ADP-ribosylated [44, 
45]. Accordingly, we hypothesize that ADP-ribosylation at C172 occurs through the formation 
of an intermediate in which acetylated K171 is transiently ADP-ribosylated. At 3.75 Å, the 
oxygen atom of the acetyl group on K171 and the C1’ atom of NAD+ in the ternary complex 
model were in close proximity to each other (within the approximate van der Waals contact 
distance) (Fig 8A). The minimum, average and maximum distances between these atoms in 
the MD trajectories were 2.83, 3.48 and 5.21 Å, respectively (Fig. 8B). Thus, it is possible 
that this acetyl group may be ADP-ribosylated. In addition, the acetyl group on K171 and the 
final ADP-ribosylation site, the thiol group of C172, are able to become close enough to each 
other to allow the translocation of the ADP-ribosyl group, given flexible conformational 
changes of the side chains of K171 and C172 (Fig 8C). To support this hypothesis, the 
distance between the sulfur atom of C172 and the oxygen atom of acetylated K171 was 
measured in the trajectories of the MD simulation of GDH 158–187. The distance showed 
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and frequently became shorter than 4.0 Å (within the approximate van der Waals contact 
distance) (Fig. 8D). Taken together these findings suggested a possible mechanism for the 




Fig 8. The distance between reactive atoms 
(A) The distance (Å) between the oxygen atom of the acetyl group on K171 and C1’ atom of NAD+ in the 
model is shown as a dotted line.  
(B) The fluctuation of the distance between the oxygen atom of acetylated K171 and C1’ atom in the course 
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(C) The possible distance (Å) between the oxygen atom of acetylated K171 and the thiol sulfur of C172. This 
conformation was produced by manual conformational changes of the side chains of acetylated K171 and 
C172 using Swiss PDB Viewer.  
(D) Fluctuation of the distance between the oxygen atom of acetylated K171 and the thiol sulfur of C172 in 
the trajectories of GDH 158–187.  
 
4. Discussion 
   Sirt4, which is localized to the mitochondria, regulates the TCA cycle and fatty acid 
oxidation [5, 7], and plays important roles in the suppression of cancers and ischemic heart 
disease [11, 12]. Sirt4 contributes to many of these biological events through its 
ADP-ribosylation activity to GDH using NAD+ as a substrate to downregulate GDH. GDH 
catalyzes the oxidative deamination of glutamate to produce α-ketoglutaric acid, which is an 
intermediate in the TCA cycle. We aimed to build structural models of human Sirt4 in 
complex with NAD+ and GDH 158–187 in order to elucidate the detailed mechanism by 
which Sirt4 regulates the metabolism. The Sirt4 models were first built by homology 
modeling and threading, and showed a common global fold. Subsequently, we docked NAD+ 
to the models that were energetically stable to build a complex model with NAD+. The 
docking pose of NAD+ in the Sirt4-NAD+ complex model was similar to that in a crystal 
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possesses a similar structure of internal grooves to Sirt5. A normal mode analysis showed that 
the helix-loop-strand structure of GDH 158–187 was maintained, which suggested that this 
fold is maintained when GDH binds Sirt4. Thus, we docked the structure of GDH 158-187 to 
the Sirt4 model and found a common docking pose among the Sirt4-NAD+-GDH 158–187 
complex models that were predicted by multiple methods. An analysis of the MD trajectories 
indicated that the Sirt4-NAD+-GDH 158–187 complex model converged towards a more 
stable structure, maintaining the global fold of the initial structure. NCA and sirtinol are 
known inhibitors of Sirt4 [5]. NCA docked with the groove with which the NCA group of 
NAD+ docked. In addition, the pose of NCA docked with the Sirt4 model was quite similar to 
those in the crystal structures of the Sir2 protein-NCA complexes (Fig 4E) [51]. Taken 
together, these findings supported the validity of the model structure.  
   The number of hydrogen bonds between NAD+ and Sirt4 in the ternary complex model 
increased after the model reached an equilibrium in the MD simulation. The corresponding 
hydrogen bonds are formed in the crystal structures of the complexes of NAD+ and the 
Sir2/Sirtuin proteins including afSir2 and hSirt5 [42, 50]. The increase in the number of the 
hydrogen bonds was followed by changes in the structures of loops in the Rossmann domain 
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observed between the apo and NAD+-bound forms of afSir2. We also observed a rotation of 
the small domain relative to the Rossmann domain in the MD simulation. It has been reported 
that the small domain rotates relative to the Rossmann domain in several Sir2/Sirtuin proteins 
including afSir2 and Sirt5 [50, 52].  
   While the KD and Km values for NAD
+ bound to Sirt4 have been unknown, the Km values 
for NAD+ bound to the other Sirtuins are approximately in the range of 10-4 – 10-6 M, which 
corresponds to -5 – -8 kcal/mol of the binding free energy [53]. The binding free energy 
(ΔGbind) of the interaction between Sirt4 and NAD
+ was calculated according to the 
MM/GBSA method and found to be similar to those of the interactions between the other 
Sirtuins and NAD+ (Table 8). ΔEelec was relatively large, which was in line with the large 
number of the hydrogen bonds between Sirt4 and NAD+ observed after the MD simulation.   
 
 
   A further trajectory analysis suggested that the distances between acetylated K171 and 
NAD+ and between acetylated K171 and C172 could become short enough to allow them to 
react with each other. These results are compatible with a possible reaction mechanism in 
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ADP-ribosylation of K171. This possibility is in line with the proposed mechanism that 
ADP-ribosylation by Sir2 proteins is mediated through an intermediate with the 
ADP-ribosylation of acetylated lysine [44]. Furthermore, it was suggested that an acetylated 
lysine residue is required when the Sir2 protein ADP-ribosylates residues other than arginine 
[45]. Thus, ADP-ribosylation at C172 through an intermediate with the ADP-ribosylation of 
K171 is a possible scenario.  
   The regulations of the metabolism by Sirt4 have a great impact on ischemic heart injury, 
the DNA damage response program, and the development of cancer and the glial cells [11, 12, 
54, 55]. Haigis et al. reported that Sirt4 downregulates the secretion of insulin from 
pancreatic β cells by inhibiting GDH in the mitochondria [5]. The inhibition of GDH by Sirt4 
in cancer cells represses the glutamine metabolism, leading to the suppression of cancer cell 
activity [54]. In vitro knockdown of Sirt4 increases the activity of GDH and promotes the 
proliferation and migration of cells [56]. The expression level of Sirt4 in breast cancer is 
correlated with those of the estrogen receptor, progesterone receptor, nuclear-associated 
antigen Ki-67 and tumor protein p53 [57]. Sirt4 and GDH are together expressed in the brain 
and play important roles in brain development and ageing [55, 58, 59]. It has been suggested 
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it is anticipated that the development of drugs that activate Sirt4 will contribute to the 
suppression of cancer and the survival of cardiomuscular cells in patients with ischemic heart 
injury. Resveratrol is an activator of Sirt1 and 5 and its action on Sirt1 may increase the 
longevity of yeast, worms, flies and mice [1, 60, 61]. In contrast, it was reported that 
resveratrol inhibits Sirt3 [62]. To our knowledge, no compounds have ever been found to 
activate Sirt4, while inhibitors of Sirt4 have been reported as discussed above [5]. Because 
loss of Sirt4 increases the secretion of insulin in mice, inhibitors of Sirt4 may have the 
potential to be used as seed compounds for glycometabolism ameliorators. Recently, 
structure-based drug design based on homology models has successfully produced various 
compounds [63, 64]. Thus, we hope that the Sirt4-NAD+-GDH 158–187 ternary complex 
model and the mechanism proposed in the present report will contribute to the development 
of the drugs that activate Sirt4 to treat cancer and ischemic heart injury.  
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Table 1. The identities and coverage of the human Sirt4 sequence to the template structures.  
 Template protein (PDB ID)a Identity Coverage 
Robetta Models afSir2 (1S7G) 34% 90% 
SWISS-MODEL1 zSirt5 (4UTN) 36% 82% 
SWISS-MODEL2 hSirt5 (4G1C) 35% 82% 
SWISS-MODEL3 hSirt5 (4G1C) 35% 82% 
a The abbreviations are the same as those in the legend of Fig 1.  
 
 
Table 2. A summary of the Ramachandran plots 
 Model 1 Model 2 Model 3 Model 4 Model 5 
SWISS-MODEL      
Favored 85.5% 83.8% 82.1% - - 
Disallowed 1.3% 0.9% 1.3% - - 
Robetta      
Favored 89.4% 88.9% 86.0% 84.7% 88.5% 
Disallowed 0.0% 0.0% 0.0% 0.0% 0.9% 
I-TASSER      
Favored 75.3% 69.8% 75.3% 70.2% 68.5% 
Disallowed 2.1% 3.4% 2.1% 4.7% 5.5% 
 
Table 3. A summary of the Verify3D results  
 Model 1 Model 2 Model 3 Model 4 Model 5 
SWISS-MODEL      
Quality a Pass Warning Warning - - 
% b 81.62 72.79 65.44 - - 
Robetta      
Quality a Pass Pass Pass Pass Pass 
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I-TASSER      
Quality a Pass Pass Pass Pass Pass 
% b 85.29 94.12 88.24 88.60 89.34 
a The quality of the model structure as judged by Verify3D 
b The percentage of the amino acid residues that scored ≥0.2 in the 3D/1D profile.  
 
Table 4. A summary of the results from ERRAT  
 Model 1 Model 2 Model 3 Model 4 Model 5 
SWISS-MODEL      
Overall quality factor 69.318 67.424 73.864 - - 
Robetta      
Overall quality factor 93.939 82.955 91.667 94.318 93.561 
I-TASSER      
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Table 5. Energy calculations 
 Model 1 Model 2 Model 3 Model 4 Model 5 
SWISS-MODEL      
Rosetta a 2348.092 3385.999 1780.065 - - 
SPDBV b -8092.796 -9112.978 -9764.719 - - 
Robetta      
Rosetta a -250.860 -194.694 -176.061 -136.892 -196.233 
SPDBV b -14517.061 -14334.614 -14792.727 -14468.494 -14835.143 
I-TASSER      
Rosetta a 1621.687 1372.388 1749.134 1447.029 1118.936 
SPDBV b -12257.712 -12059.712 -11537.371 -12181.420 -11788.820 
a The energy score calculated by the Score algorithm of Rosetta.  
b The energy calculated using Swiss PDB Viewer (kJ/mol).  
 
 
















a The percentage of amino acid residues that scored ≥ 0.2 in the 3D/1D profile.  
b The quality of the model structure, as judged by Verify3D 
c The energy score calculated using the Score algorithm of Rosetta.  
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Table 7. Distances (Å) between NAD+ and the hydrogen bond-forming residues before and after the MD 
simulation  
timing E68 Q143 N144 D146 S262 N286 G288 
0 ns 6.54 2.98 4.55 3.31 3.00 2.81 4.14 
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Table 8. The free energy change associated with NAD+ binding to the Sirt4 model and its energy components in 
kcal/mol 
Energetics Values 
ΔEvdw -75.2 ± 0.5 
ΔEelec -280 ± 2 
ΔEMM -355 ± 2 
TΔSMM -81.3255 
ΔGMM -274 
ΔGsolvpolar  279 ± 2 
ΔGsolvnonpolar  -9.03 ± 0.02 
ΔGsolv 270 ± 2 
ΔGbind   -4 
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